瑞他鲁肽 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-21 and is reviewed periodically as new material appears.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
| Property | Value | Notes |
|---|---|---|
| 研究代号 | LY3437943 | 文献中常用的实验标识 |
| 药物类别 | 三重受体激动剂 | 靶向GLP-1、GIP与胰高血糖素受体 |
| 开发状态 | 后期临床研究 | 尚未获批上市 |
| 主要研究人群 | 肥胖与2型糖尿病 | 入组条件依试验方案而定 |
| 常见同义词 | 瑞他鲁肽；LY3437943 | 名称拼写可能因语言和出版物而异 |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
There is no scientific evidence that HCG is effective in the treatment of obesity. The meta-analysis found insufficient evidence supporting the claims that HCG is effective in altering fat-distribution, hunger reduction, or in inducing a feeling of well-being. The authors stated "…the use of HCG should be regarded as an inappropriate therapy for weight reduction…" In the authors opinion, "Pharmacists and physicians should be alert on the use of HCG for Simeons therapy. The results of this meta-analysis support a firm standpoint against this improper indication. Restraints on physicians practicing this therapy can be based on our findings." According to the American Society of Bariatric Physicians, no new clinical trials have been published since the definitive 1995 meta-analysis. The scientific consensus is that any weight loss reported by individuals on an "HCG diet" may be attributed entirely to the fact that such diets prescribe calorie intake of between 500 and 1,000 calories per day, substantially below recommended levels for an adult, to the point that this may risk health effects associated with malnutrition.
A common pathological cause for a high BMR is fever, since a rise in body temperature increases the rate of cellular metabolic reactions. It is estimated that for every degree Fahrenheit of rise in body temperature, the BMR increases by 7 percent. Thyroid disease also has a marked effect on BMR, since thyroid hormones regulate the rate of cellular metabolism. Hyperthyroidism—in which there is an increase in the production of thyroid hormones—leads to a high BMR, while hypothyroidism—in which thyroid hormones are depleted—causes a low BMR. Prolonged periods of abnormal nutrition cause an adaptive change in BMR; this helps the body to maintain a stable body weight in response to the change in food supply. In prolonged malnutrition, the BMR declines, while in prolonged overnutrition, the BMR is increased. Cancer sometimes causes an increase in BMR, perhaps because the cancer cells that form tumors have a high level of metabolic activity.
== Silicon-29 == Silicon-29 is of note as the only stable silicon isotope with a nonzero nuclear spin (I = 1/2). As such, it can be employed in nuclear magnetic resonance and hyperfine transition studies, for example to study the properties of the so-called A-center defect in pure silicon.
[Citation Needed] All of the above have been, owing to their somewhat sophisticated yet straightforward synthesis from pharmaceutical opioids, consistently if in vanishingly small quantities since at least the 1960s by law enforcement around the world as the results of clandestine synthesis, and acetylmorphone itself was banned by the League of Nations in 1930 to prevent its use as a legal heroin substitute.[Citation Needed][Relevance] Therefore, all or most of this group and its hydromorphone analogues along with some others more closely related to heroin such as acetylpropionylmorphine were the first designer drugs in the 1920s.
Sources: en.wikipedia.org
The greater sac, represented in red in the diagrams above. The lesser sac, represented in blue. The lesser sac is divided into two "omenta": The lesser omentum (or hepatogastric) is attached to the lesser curvature of the stomach and the liver. The greater omentum (or gastrocolic) hangs from the greater curvature of the stomach and loops down in front of the intestines before curving back upwards to attach to the transverse colon. In effect it is draped in front of the intestines like an apron and may serve as an insulating or protective layer. The mesentery is the part of the peritoneum through which most abdominal organs are attached to the abdominal wall and supplied with blood and lymph vessels and nerves.
== Principles and history == Water was the original coolant for internal combustion engines. It is cheap, nontoxic, and has a high heat capacity. It however has only a 100 Kelvin liquid range, and it expands upon freezing. To address these problems, alternative coolants with improved properties were developed. Freezing and boiling points are colligative properties of a solution, which depend on the concentration of dissolved substances. Salts, for example, lower the melting points of aqueous solutions and as such are commonly used for de-icing due to their low cost. However, salt solutions typically cannot be used in cooling systems because they induce corrosion of metals. Solutions of organic compounds, especially alcohols, in water are effective. Alcohols such as methanol, ethanol, ethylene glycol, etc. have been the basis of all antifreezes since they were commercialized in the 1920s.
Aviv (1981), surgeon known for inventing the Flexible Endoscopic Evaluation of Swallowing with Sensory Testing technique and developing the transnasal esophagoscopy method Adrian R. Krainer (1981), co-winner of the 2018 Breakthrough Prize in Life Sciences Neil Shubin (1982), paleontologist and co-discoverer of Tiktaalik, provost of the Field Museum of Natural History Michael Travisano (1983), evolutionary biologist and professor at University of Minnesota, Twin Cities Peter Lunenfeld (1984), critic and theorist of digital media Peter Marks (1985), director of the Center for Biologics Evaluation and Research and member of the White House Coronavirus Task Force James Nowick (1985), professor of chemistry at the University of California, Irvine Eric M. Genden (1987), head and neck surgeon who performed the first jaw transplant using the patient's jaw and bone marrow Geoffrey Miller (1987), psychologist, professor at the University of New Mexico Leslie B. Vosshall (1987), neurobiologist known for her contributions in the field of olfaction Patrick Ball (1988), data scientist, executive director of the Human Rights Data Analysis Group Rebecca N. Wright (1988), computer scientist and professor at Barnard College, former director at DIMACS Jonathan Rosand (1989), professor of neurology at Harvard Medical School, son of art historian David Rosand '59 Christopher S.
== History == The term "hydrocolloid" was coined in the 1960s during the development of mucoadhesives, first used to treat mouth ulcers. The term was later adopted for a new dressing type in which a hydrophilic gelable mass was applied to a flexible semipermeable carrier. It was first sold under the brand Granuflex in the United Kingdom in 1982, and then DuoDERM in the United States in 1983. Different products subsequently came to market with slightly varying formulations, designed for specific areas of the body or specific purposes (for example, postoperative dressings). More recently, the term has sometimes been used to describe hydrogel dressings which are fundamentally different to hydrocolloid dressings.
Following Val Belcher's retirement from professional football, Belcher began a successful career as a restaurant entrepreneur. In 1986, Belcher founded the Lone Star Cafe restaurant with former Ottawa Rough Rider teammate Larry Brune in the Ottawa suburb of Nepean. Over the years, it expanded into a franchise business. It was renamed Lone Star Texas Grill, operating under the Lone Star Group of Companies. As of 2020, Lone Star Texas Grill operates over 20 locations across southern and eastern Ontario, including seven in the Greater Ottawa Area where it originated, as a family-style restaurant specializing in wood-fire grill fajitas, authentic Tex-Mex fare and frozen margaritas.
Sources: en.wikipedia.org
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。
司美格鲁肽主要靶向GLP-1受体，而瑞他鲁肽同时作用于GLP-1、GIP和胰高血糖素受体。这种三重机制旨在产生不同的代谢效应，但临床差异仍需头对头研究确认。
长期心血管结局、停药后维持效果、罕见不良事件和不同人群中的获益风险比尚未完全确定。完整三期数据和监管审评将影响结论。
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。